Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.
Clinicians have long known that a substantial proportion of patients treated with high-dose glucocorticoids experience a variety of serious side effects, including metabolic syndrome, bone loss, and mood shifts, such as depressive symptomatology, manic or hypomanic symptoms, and even suicide. The reason for individual variability in expression or severity of these side effects is not clear. However, recent emerging literature is beginning to shed light on possible mechanisms of these effects. As an introduction to this volume, this chapter will review the basic biology of glucocorticoid release and molecular mechanisms of glucocorticoid receptor function, and will discuss how dysregulation of glucocorticoid action at all levels could contribute to such side effects. At the molecular level, glucocorticoid receptor polymorphisms may be associated either with receptor hypofunction or hyperfunction and could thus contribute to differential individual sensitivity to the effects of glucocorticoid treatment. Numerous factors regulate hypothalamic-pituitary-adrenal (HPA) axis responsiveness, which could also contribute to individual differences in glucocorticoid side effects. One of these is sex hormone status and the influence of estrogen and progesterone on HPA axis function and mood. Another is immune system activity, in which immune molecules, such as interleukins and cytokines, activate the HPA axis and alter brain function, including memory, cognition, and mood. The effects of cytokines in inducing sickness behaviors, which overlap with depressive symptomatology, could also contribute to individual differences in such symptomatology. Taken together, this knowledge will have important relevance for identifying at-risk patients to avoid or minimize such side effects when they are treated with glucocorticoids. A framework for assessment of patients is proposed that incorporates functional, physiological, and molecular biomarkers to identify subgroups of patients at risk for depressive symptomatology associated with glucocorticoid treatment, and for prevention of side effects, which in many cases can be life-threatening.
Marques
Andrea H
AH
Section on Neuroendocrine Immunology and Behavior, Integrative Neural Immune Program, National Institute of Mental Health, National Institutes of Health, Rockville, Maryland, USA.
Silverman
Marni N
MN
Sternberg
Esther M
EM
D000818:Animals; D003072:Cognition Disorders / Q000139:chemically induced / Q000503:physiopathology; D003866:Depressive Disorder / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D005544:Forecasting; D005938:Glucocorticoids / Q000494:pharmacology*; D012739:Gonadal Steroid Hormones / Q000494:pharmacology; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D011965:Receptors, Glucocorticoid / Q000819:agonists / Q000037:antagonists & inhibitors
D005938:Glucocorticoids; D012739:Gonadal Steroid Hormones; D011965:Receptors, Glucocorticoid